Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2395903 | 0.78 | KIT (0.38) | KITGHSRKMT2A | |
| SCHEMBL22395062 | 0.78 | TSHR (0.37) | MAPK1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL10163801 | 0.76 | NR1H4 (0.37) | MEN1KMT2ANPSR1 | |
| SCHEMBL22148596 | 0.74 | KIT (0.39) | KITGHSRAKT1 | |
| SCHEMBL9886441 | 0.74 | KIT (0.34) | KITGHSRAKT1BDKRB1CYP2C9 | |
| SCHEMBL9886398 | 0.74 | KIT (0.34) | KITGHSRAKT1BDKRB1MEN1 | |
| SCHEMBL12888955 | 0.73 | CHRM2 (0.35) | CRHR1 | |
| SCHEMBL19033003 | 0.73 | CHRM2 (0.33) | CRHR1 | |
| SCHEMBL22395107 | 0.72 | GPR119 (0.35) | GPR119 | |
| SCHEMBL22395115 | 0.71 | AKT1 (0.38) | KITGHSRAKT1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-09-29 | — | — | US | disclosed |
| EP-3962914-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-02-01 | — | — | US | disclosed |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-02-01 | — | — | US | disclosed |
| CN-113767101-A | Novel indole-2-carboxamides having anti-Hepatitis B Virus (HBV) activity | 艾库里斯有限及两合公司 | 2021-12-07 | — | — | CN | disclosed |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-06-17 | — | — | US | disclosed |
| WO-2020221826-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
| WO-2020221826-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2020-11-05 | — | — | WO | disclosed |
| EP-3704119-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2020-09-09 | — | — | EP | disclosed |
| US-20120252817-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252817-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252817-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| WO-2010141273-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | WO | disclosed |
| EP-2225238-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | Boehringer Ingelheim International GmbH (DE) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070485-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | HPGDS, COL14A1, ARG1 | KIT 800/4885GHSR 1989/4885AKT1 4444/4885 |
| US-20120252817-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | ARG1, COL14A1, HPGDS | KIT 776/4885GHSR 1899/4885AKT1 4478/4885 |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | CDK2, HCCS, BRD4 | KIT 4225/4885GHSR 4401/4885AKT1 908/4885 |
| US-20220306647-A1 | NOVEL INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITUS B VIRUS (HBV) | HCCS, IDO1, BRD4 | KIT 4022/4885GHSR 2054/4885AKT1 1871/4885 |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | HCCS, BRD4, CDK2 | KIT 4075/4885GHSR 4400/4885AKT1 998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.